Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma, Alveolar 1Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1

Interventions

Doxorubicin 6Ifosfamide 5Radiotherapy 4pazopanib 3cediranib 3atezolizumab 3Sunitinib 3selinexor 2perifosine 2pembrolizumab 2Trabectedin 2Specimen Handling 2Loperamide 2Gemcitabine 2Filgrastim 2Dacarbazine 2Cisplatin 2Biopsy 2Bevacizumab 2trifluridine tipiracil drug combination 1spartalizumab 1sargramostim 1romidepsin 1lentiviral minigene vaccine of COVID-19 coronavirus 1ixazomib 1indolepropanol phosphate 1futibatinib 1fludarabine 1cabozantinib 1brostallicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × Crizotinib × Sarcoma × Clear all
NCT01524926 2023-12-11

CREATE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
582 enrolled
LymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Sarcoma, Clear Cell, Rhabdomyosarcoma, Alveolar, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡